Introduction
Cell cycle progression is driven by the sequential activation and inactivation of cyclin-dependent kinases (CDKs). CDK activity is regulated at dierent levels (Morgan, 1995) , including association with a cyclin regulatory subunit, phosphorylation/dephosphorylation cycles and association with a number of negative regulatory proteins known as CKI (for CDK inhibitors) (Elledge et al., 1996; Sherr and Roberts, 1995) . The CIP/KIP family of mammalian CKIs consists of three members, p21 CIP1/WAF1/SDI1 (hereafter referred to as p21), p27 KIP1 and p57
KIP2
, which contain discrete CDK and cyclin-binding domains (Chen et al., 1996; Goubin and Ducommun, 1995; Lin et al., 1996; Russo et al., 1996) . CIP/KIP proteins regulate cell proliferation through the modulation of cyclin/CDK complexes activity in response to various intracellular or extracellular signals (Elledge et al., 1996; Sherr and Roberts, 1995) . p21, for instance, is a key mediator of the G1 growth arrest induced by the tumor suppressor protein p53 in response to DNA damage (Brugarolas et al., 1995; Deng et al., 1995; Waldman et al., 1995) . A unique feature of p21 that distinguishes it from the other CKIs is its capacity to bind to the Proliferating Cell Nuclear Antigen (PCNA), a processivity factor for DNA polymerase d and e, that is essential for both DNA replication and DNA repair (Gulbis et al., 1996; Kelman, 1997) . We have recently shown that p21 binding to PCNA is sucient to inhibit cell cycle progression at the G1/S and G2/M transitions in human cancer cells . p21 may therefore inhibit cell cycle progression by two independent mechanisms, inhibition of cyclin/CDK complexes and/or inhibition of PCNA function. The eectiveness of these two mechanisms is likely to be determined by the relative abundance of p21, CDKs and PCNA. Furthermore, the abundance of the p21 protein may also determine whether p21 acts as an inhibitor or as an assembly factor of cyclin/CDK complexes, since it has recently been found that at low concentration p21 promotes the assembly of active kinase complexes, whereas at higher concentrations it inhibits activity (LaBaer et al., 1997) . It is therefore critical to better understand the molecular mechanisms underlying the regulation of p21 levels.
Although most studies have focused on the mechanisms of transcriptional regulation of p21, it has recently been shown that p21 expression can also be regulated at the level of protein stability. Overexpression of the transcription factors C/EBPa (Timchenko et al., 1996) or p120 E4F (Fernandes et al., 1998) was shown to result in a signi®cant increase of p21 half-life. In addition, p21 has been found to be ubiquitinated in vivo (Maki and Howley, 1997) suggesting that p21 levels may be regulated by the ubiquitin-proteasome pathway. This system plays a key role in cell cycle control by regulating the abundance of a number of regulatory proteins, including the human CKI p27 (Pagano et al., 1995) and the yeast CKIs Sic1p (Verma et al., 1997) and Far1p (Henchoz et al., 1997) . Although p21 was initially thought not to be regulated by the proteasome-dependent pathway (Pagano et al., 1995) , more recent studies indicate that proteasome mediated proteolysis may play a role in the regulation of p21 abundance (Blagosklonny et al., 1996; Maki and Howley, 1997) .
Here, we report that p21 expression levels and stability in p53-de®cient cells are regulated by the proteasome-dependent proteolytic pathway and that this regulation is abrogated when p21 is expressed to very high levels. Futhermore, we show that p21 mutants de®cient for interaction with either CKDs or PCNA exhibit respectively, decreased and enhanced sensitivity to proteasome-mediated degradation. Association with cyclin/CDKs complexes may therefore facilitate p21 degradation while binding to PCNA may protect p21 from proteasome-dependent proteolysis. These later results suggest that association of p21 with its dierent partners regulates p21 expression levels and stability in vivo.
Results
Proteasome-dependent degradation modulates p21 protein levels and stability in vivo Proteasome inhibitors have previously been shown to upregulate p21 expression levels in human cancer cells. This eect was most signi®cant in cell lines expressing wild-type p53 and appeared to be due in part to p53-dependent increase in p21 mRNA levels (Blagosklonny et al., 1996; Maki and Howley, 1997) . To further characterize the role of the proteasome in the regulation of p21 stability in vivo, and to overcome the limitations due to p53-dependent transactivation of the p21 promoter, we expressed wild-type and mutant HA-tagged p21 proteins, under the control of a tetracycline-regulated promoter, in the p53-de®cient human colon cancer cell line DLD1, which constitutively expresses very low levels of endogenous p21 (Waldman et al., 1996) . We have previously shown that ectopic expression of p21 in stably transfected DLD1 cell lines was virtually null in the presence of tetracycline and was only induced after removal of tetracycline from the culture media for 48 ± 72 h . Quantitative immunoblotting experiments indicated that p21 levels after tetracycline withdrawal were similar or even lower than those observed in normal human ®broblasts after UV irradiation .
In an initial set of experiments we tested the eects of various proteasome inhibitors on wild-type p21 accumulation in DLD1 transfectants 4 days after tetracycline removal (Figure 1a) . We found that p21 levels were markedly upregulated after treatment of the cells with the peptide aldehyde LLnL (N-acetyl-leu-leunorleucinal or calpain inhibitor I), which has previously been shown to inhibit proteasome-mediated proteolysis (Rock et al., 1994) . Other protease inhibitors were used to demonstrate that LLnLinduced p21 upregulation results from proteasome speci®c inhibition, since LLnL also inhibits nonproteasomal proteases such as calpains and lysosomal cysteine proteases (e.g., cathepsins). LLM (N-acetylleu-leu-methional or calpain inhibitor II), a peptide aldehyde structurally related to LLnL, which inhibits calpains and cathepsins but has no eect on proteasomal proteases, did not enhance p21 levels. Similarly, E-64d, another inhibitor of calpains and cathepsins, had no detectable eect on p21 expression in DLD1 transfectants. In contrast, lactacystin and MG132, two highly speci®c inhibitors of proteasomal activity (Fenteany et al., 1995; Palombella et al., 1994) were able to upregulate p21 levels. On longer exposures of the Western blots, higher molecular weight forms of p21 were clearly detected in cells treated with LLnL ( Figure 1b) . In contrast, no change in electrophoretic mobility of p21 was observed in cells treated with LLM Pulse-chase experiments were conducted as in (c) and p21 35 Slabelled proteins were quantitated using a STORM840 imager. Results are expressed relative to the amount of p21 at the beginning of the chase (0 min) or dimethylsulfoxide (DMSO), indicating that the accumulation of higher molecular weight forms of p21 resulted from proteasome-speci®c inhibition. Similar high molecular weight forms of p21 have recently been found to accumulate in the U2OS osteosarcoma cell line treated with MG132 and were shown to correspond to ubiquitinated forms of p21 (Maki and Howley, 1997) . Together, these results indicate that p21 levels in human DLD1 colon cancer cells are regulated by proteasome-dependent degradation.
We then investigated whether the upregulation of p21 levels in cells treated with proteasome inhibitors was due to enhanced p21 protein stability. We ®rst measured the metabolic half-life of p21 in untreated DLD-1 transfectants by performing a pulse-chase analysis. We found that p21 had a relatively short half-life of about 60 min, which is consistent with the previously reported half-life of endogenous p21 in U2OS cells (Maki and Howley, 1997) . In addition to p21, several speci®c proteins corresponding to the known p21 partners were detected in the immunoprecipitates ( Figure 1c ). They were identi®ed by a combination of immunoprecipitations with speci®c antibodies and V8 protease mapping as CDK2, CDK4, PCNA, cyclin D1 and cyclin A (data not shown).
Next, we investigated whether proteasome inhibitors might increase the metabolic half-life of p21. For this purpose, pulse-chase analyses were performed with DLD-1 transfectants expressing p21 and treated with LLnL, LLM or DMSO alone. As shown in Figure 1d , p21 half-life was markedly increased (to about 3 h) in cells treated with proteasome inhibitor LLnL, compared with cells treated with LLM or DMSO alone ( Figure 1d ). Essentially identical results were obtained using MG132 instead of LLnL (data not shown). Together, these data support the notion that proteasome-dependent degradation plays an important role in the regulation of p21 levels and stability. p21 mutants de®cient for interaction with CDKs or PCNA exhibit dierential stability in vivo To examine whether the interaction between p21 and its associated partners, PCNA and CDKs, modulates p21 stability, we made use of point mutants of p21 impaired in either one or the other interaction . The p21 CDK7 mutant contains three amino-acid substitutions (W49R, F51S and D52A) in residues that are conserved in the related CKI p27kip1 and are known to make critical contacts with CDK2 (Russo et al., 1996) , while the p21 PCNA7 mutant carries mutations in three residues (M147A, D149A and F150A) that have been shown to bind to a hydrophobic pocket under the connector loop of PCNA (Gulbis et al., 1996) . The point mutations introduced into the p21 PCNA7 and p21 CDK7 mutants are unlikely to provoke major structural changes in p21 since we have previously shown that these mutants are correctly targeted to the nucleus and associate, as predicted, with all the other partners of p21 . DLD1 cell lines were engineered to express the p21 PCNA7 and p21 CDK7 mutants under the control of a promoter regulated by the tetracycline-responsive tTA transactivator . Screening of clones for conditional expression of p21 mutant proteins by indirect immuno¯uorescence microscopy, revealed striking dierences in the expression levels of the two mutants. All clones (n=7) corresponding to mutant p21 CDK7 , which is impaired in the interaction with CDKs, exhibited strong nuclear signals, as illustrated in Figure 2a . In contrast, all clones (n=6) expressing mutant p21 PCNA7 , de®cient for interaction with PCNA, showed low levels of nuclear staining (Figure 2b ). Western blot analysis indicated that dierences in nuclear staining are likely to be due to dierences in steady state levels of p21 CDK7 and p21 PCNA7 mutant proteins (Figure 2c ). Similar results were obtained with a polyclonal antiserum directed to the carboxy-terminal part of p21 (data not shown). Since both p21 mutants are expressed under the control of the same tetracycline-regulated promoter, we examined the possibility that dierences in expression levels may result from dierences in stability. Pulse chase analysis of p21 CDK7 and p21 PCNA7 stability was performed, in representative DLD1 transfectants, as described above for wild-type p21. This analysis revealed that p21 CDK7 is a much more stable protein than p21 PCNA7 (Figure 3 ). Whereas the half-life of Indirect immuno¯uorescence analysis of HA-tagged p21 CDK7 (a) or p21 PCNA7 (b) expression in two independent clones, using anti-HA monoclonal antibody and anti-mouse Texas Red-conjugated secondary antibody. Immuno¯uorescence staining were performed on the same day, with the same solutions and the same incubation times. The same short exposure time (30 s) was used for all clones to reveal dierences in staining intensity. (c) Whole cell extracts of HA-tagged p21 CDK7 or p21 PCNA7 clones presented in (a) and (b) (corresponding to 5610 4 cells) were subjected to Western blot analysis using anti-HA antibody p21 PCNA7 mutant is approximately 30 min, the half-life of p21 CDK7 is more than fourfold longer, around 140 min (Figure 3c and d) . Analysis of the immunoprecipitated 35 S-labelled proteins also con®rmed that the mutant p21 CDK7 was unable to interact with CDKs or cyclins but associated with PCNA as expected (Figure 3a) . This indicates that the cyclin-binding site which is intact in mutant p21 CDK7 is not sucient to promote stable association with cyclin-CDK complexes in vivo and suggests that the enhanced stability of this p21 CDK7 mutant may result from the loss of association with cyclin-CDK complexes. In contrast, association with PCNA may stabilize p21 since the mutant p21 PCNA7 which failed to interact with PCNA but was associated with CDKs and cyclins, had a signi®cantly shorter half-life than wild-type p21 (Figure 3b) . The half life of the p21 PCNA7 mutant (approximately 30 min) was reproducibly found to be at least two fold lower than that of wild-type p21 (Figure 3d) . Together, these results suggest that association of p21 with cyclin-CDK complexes may enhance p21 turnover while association with PCNA may favour p21 stability.
Enhanced stability of p21
CDK7 mutant is due to reduced proteasome-dependent degradation
Since the p21 CDK7 mutant causes G1 and G2/M cell cycle blocks in DLD1 cells while the p21 PCNA7 mutant fails to arrest cell cycle progression , we examined the possibility that dierences in stability of the two mutants may result from their dierential eects on cell cycle progression. For this purpose, we performed pulse-chase experiments in cells treated with lovastatin, a drug that arrests cell cycle progression at the G1/S transition. We found that the half-lives of the two mutants p21 CDK7 and p21 PCNA7 in lovastatin-treated cells were nearly identical to their half-lives in untreated cells (Figure 3d ), indicating that dierences in stability are unlikely to be due to cell cycle blockade. This is further con®rmed by the fact that p21 and p21 CDK7 mutant, which cause similar G1 and G2 growth arrest , exhibit dierent stabilities in vivo (Figures 1 and 3) . In addition, the results obtained with lovastatin, an inhibitor of HMG-CoA (3-hydroxy-3-methylglutaryl coenzyme A) reductase which blocks the posttranslational modi®cation (isoprenylation) of small GTP binding proteins such as Rho and Ras, indicate that small GTP binding proteins are not involved in p21 degradation. In contrast, both Rho and Ras have been suggested to play an important role in the degradation of the related CKI p27 (Hirai et al., 1997; Kawada et al., 1997) .
We then investigated whether enhanced stability of p21 CDK7 mutant may result from a reduced proteasome-dependent degradation. For this purpose, the DLD1 cell lines expressing p21 CDK7 and p21 PCNA7 half-lives. Halflives were deduced from the quantitative analysis of pulse-chase data. p21 CDK7 and p21 PCNA7 half lives were reproducibly found to be at least twofold longer and twofold shorter than that of wild type p21, respectively (relative variability: +10%). Treatment with lovastatin (60 mM, 48 h), a drug that blocks cell cycle progression in G1, did not change signi®cantly p21 or p21 mutants half-lives proteins were treated with proteasome inhibitors, LLnL, lactacystin and MG132, or non-proteasome inhibitors LLM and E-64d, and expression levels of the two p21 mutants were analysed by Western blot (Figure 4a ). All the inhibitors tested had minimal eects on the accumulation of the p21 CDK7 mutant, which was already higher in untreated cells, than wildtype p21 (Figure 1a ) or p21 PCNA7 mutant (Figure 4a ). In contrast, expression levels of the p21 PCNA7 mutant were signi®cantly upregulated in DLD1 transfectants treated with LLnL, lactacystin and MG132, compared to untreated cells or cells treated with LLM and E-64d. To extend these ®ndings, we determined the eects of proteasome inhibitors on p21 CDK7 and p21 PCNA7 metabolic half-lives (Figure 4b ). Pulse-chase experiments revealed that the half-life of p21 PCNA7 was increased by more than threefold, from 30 ± 105 min, in cells treated with proteasome inhibitor LLnL, compared with cells treated with DMSO alone or with LLM. In contrast, inhibition of proteasomal activity had minimal eects on the half-life of p21 CDK7 , which only increased from 140 min in untreated cells to 200 min in cells treated with LLnL. This later result suggests that enhanced stability of the mutant p21 CDK7 may result from reduced sensitivity to proteasome-dependent degradation.
High levels of p21 expression overcome proteasomedependent regulation of p21 stability
We examined whether high levels of p21 expression may alter proteasome-dependent regulation of p21 stability. Quantitative immunoblotting experiments Figure 4 Dierential eects of proteasome inhibitors on expression levels and stability of p21 mutants de®cient for interaction with CDKs or PCNA. (a) Western blot analysis of p21 mutant expression after proteasome inhibitor treatment. DLD1 cell lines expressing HA-tagged p21 CDK7 and p21
PCNA7
were treated with the indicated inhibitors. Total cell extracts were subjected to Western blot analysis using anti-HA antibody. (b) Half-lives of wild-type p21 and p21 mutants, p21 CDK7 and p21 PCNA7 , in cells treated with proteolysis inhibitors. DLD1 cells expressing p21 CDK7 or p21 PCNA7 protein were treated with LLM (50 mM), LLnL (50 mM) or DMSO alone, for 14 h. Pulse-chase analysis of the p21 proteins half-lives was performed in the presence of the inhibitor, as described in Figure 1c , d have previously revealed that the tetracycline-regulated expression system results in moderate levels of p21 expression. To obtain high expression levels, we performed transient transfection experiments with a p21 construct under the control of a cytomegalovirus promoter. Western blot analysis show that indeed p21 or p21 mutants levels were 10 ± 20-fold higher than those observed in the stable tetracycline-regulated system (Figure 5a ). Transfected DLD1 cells were then treated with MG132 to determine whether p21 stability is still regulated by proteasome-dependent degradation when p21 is expressed to high levels. We found that inhibition of proteasomal activity did not result in a signi®cant upregulation of expression levels of p21 or the p21 CDK7 and p21 PCNA7 mutants (Figure 5b) . Moreover, the half-lives of transiently expressed p21, p21 CDK7 and p21
were similar for the three proteins and, for p21 and p21 PCNA7 mutant, significantly longer than those measured in the stable tetracycline-regulated expression system (Figure 5c and d). Together, these results suggest that high levels of p21 expression overcome proteasome-dependent regulation of p21 stability. Although the immunoprecipitations patterns of p21-associated proteins in transiently transfected cells were similar to those observed in the stable tetracycline-regulated system (compare Figures 1c, 3a, 3b, 5c ), a noticeable dierence was the rapid disappearance of p21-associated-cyclin D after 1 h of chase in transiently transfected cells expressing wild-type p21 or mutant p21
. The absence of p21 association with cyclin D-containing complexes may somewhat contribute to the enhanced stability and resistance to proteasome degradation of p21 in transiently transfected cells.
Discussion
In addition to its role as an inhibitor, p21 has recently been shown to act as an adaptor protein for cyclin/ CDK complexes (LaBaer et al., 1997) . Whereas at high concentration, p21 inhibits kinase activity, at low concentration it was found to promote the assembly of active cyclin/CDK complexes. The concentrationdependence of these two opposite eects suggests that slight variations of p21 levels may determine whether p21 inhibits or stimulates cell proliferation. It is therefore very important to better characterize the mechanisms involved in the regulation of p21 expression levels in vivo. In this study, we show that p21 abundance and stability are regulated by the proteasome-dependent pathway and by association with its partners, CDKs and PCNA. Furthermore, we demonstrate that this proteasome-mediated regulation of p21 levels is abrogated when p21 is expressed to high levels.
Our results show that proteasome-mediated proteolysis plays an important role in the regulation of p21 levels. Inhibition of proteasome-dependent degradation in p53-negative human colon cancer cells, conditionally expressing p21, resulted in a signi®cant increase of both p21 half-life (more than 2.5-fold) and steady-state levels (sevenfold) compared to untreated cells. Interestingly, the half-life of p21 after inhibition of proteasomal activity (160 min) was similar to that, in untreated cells, of a p21 point mutant (p21 CDK7 ) speci®cally aected for the binding to CDKs (140 min). The half-life of the p21 CDK7 mutant was only slightly increased after proteasome inhibitor treatment indicating that this mutant has a greatly reduced sensitivity to proteasome-mediated proteolysis. Although this mutant contains an intact cyclin-binding site, it does not appear to be able to interact with cyclin-CDK complexes in vivo (Figure 3a) . This suggests that the enhanced stability of the p21 CDK7 mutant results from the loss of association with cyclin-CDK complexes. This hypothesis is supported by our observation that the point mutations introduced into this p21 CDK7 mutant do not aect other properties of p21, including the association with other partners such as PCNA, the targeting to the nucleus and the capacity to cause G1 and G2 growth arrest in DLD1 cells . Binding of p21 to cyclin/CDK complexes may therefore play an active role in proteasome-dependent degradation of p21, similarly to what has been found for the related human CKI p27 (Shea et al., 1997; Vlach et al., 1997) or the yeast CKIs Sic1p (Verma et al., 1997) and Far1p (Henchoz et al., 1997) . Proteasome-mediated degradation of these three CKIs has been shown to be dependent on association with active G1 cyclin/CDK complexes and on phosphorylation of these inhibitors. In the case of p27, degradation was speci®cally triggered by cyclin E-CDK2 complexes while cyclin D1/CDK4 complexes had no eects on p27 levels (Shea et al., 1997; Vlach et al., 1997) . We found that p21 was phosphorylated by cyclin E-CDK2 and cyclin A-CDK2 complexes in vitro (data not shown). However, this phosphorylation was not sucient to trigger proteasome-dependent degradation of p21 in an in vitro assay using rabbit reticulocyte lysate or human cell extracts as source of ubiquitinating enzymes and proteasome complexes (C.C and B.D, unpublished data). Therefore, although it is reasonable to think that phosphorylation-dependent mechanisms could control proteasome-mediated degradation of p21, it remains to be demonstrated that p21 is phosphorylated by cyclin/CDK complexes in vivo, to identify the cyclin/ CDK involved and the target sites on p21, and ®nally to determine the consequences of these phosphorylation events on p21 half-life and steady-state levels. In this respect, it will be important to examine the potential role of cyclinD-containing complexes in these processes since we observed that the loss of p21 association with these complexes in cells overexpressing p21 was correlated with an enhanced stability of p21.
Other proteins, in addition to cyclin/CDK complexes, may also regulate proteasome-mediated degradation of p21. Our data suggest a role for PCNA in protecting p21 from degradation since half-life of a mutant de®cient for interaction with PCNA (p21 PCNA7 ) was decreased twofold compared to wild-type p21 (30 min instead of 60 min). Biochemical analysis provide evidence that this p21 PCNA7 mutant, which carries single-point mutations in three residues critical for PCNA binding, is only de®cient for PCNA interaction and is still capable to associate with cyclins and CDKs (Figure 3a) . Therefore, the enhanced degradation of p21 PCNA7 is likely to result from the speci®c inability of this mutant protein to associate with PCNA. PCNA could protect p21 from proteasome-dependent degradation by either direct or indirect mechanisms. For example, PCNA could sequester p21 in speci®c subcellular compartments or in insoluble complexes. In agreement with this later possibility, we recently found that a signi®cant fraction of wild-type p21 and p21 CDK7 mutant, but not p21 PCNA7 mutant, is associated with PCNA in insoluble complexes . Alternatively, PCNA binding may mask signals on p21 that target it for degradation by the proteasome. The pRb tumor suppressor protein, for instance, has been shown to use a similar mechanism to protect E2F transcription factor from ubiquitin-proteasome-dependent degradation (Campanero and Flemington, 1997; Hateboer et al., 1996; Hofmann et al., 1996) . Whatever the precise mechanisms involved, our results provide genetic and biochemical evidence that protein-protein interactions play a key role in the modulation of proteasomemediated degradation of p21, and suggest that association of p21 with cyclin/CDK promotes its degradation while association with PCNA enhances its stability. Proteasome-dependent degradation of p21 may also be regulated by the abundance of p21 itself. Our data show that overexpression of p21 in transiently transfected cells abrogates regulation by the proteasome-dependent pathway ( Figure 5 ). Similar results were recently reported for p27 (Vlach et al., 1997) . In that case, it was found that, unlike endogenous p27, retrovirally expressed wild-type p27 was not regulated by proteasome-dependent degradation and it was proposed that this was due to the inhibition, by overexpressed p27, of the activity of cyclin/CDK complexes required for its degradation (Vlach et al., 1997) . It remains to be seen whether a similar mechanism could explain our observation that high levels of p21 expression overcome proteasome-dependent regulation. However, these results suggest, that in physiological situations where p21 is expressed to high levels, for instance after DNA damage or during dierentiation processes, abrogation of proteasomedependent degradation may further enhance p21 accumulation. Therefore, p21 expression levels in vivo are likely to be regulated by dierent mechanisms, including transcriptional and post-translational mechanisms, that may cooperate in certain situations. Further characterization of the mechanisms controlling p21 abundance will provide a better understanding of the regulation of p21 function in various biological processes.
Materials and methods
Plasmids, cell culture and transfections pcDNA3-p21 plasmid was constructed by inserting a HindIII/XbaI fragment containing p21cDNA from pBluescript-p21 into HindIII/Xba1 sites of pcDNA3 vector. p21 cDNA was then changed to p21HA-tagged cDNA by replacing a EcoRI/BamHI fragment from pcDNA3-p21 plasmid by a EcoRI/BamHI fragment from pUHD10-p21HA to generate pcDNA3-p21HA plasmid. A similar strategy was used to construct pcDNA3-p21 CDK7 HA and pcDNA3-p21 PCNA7 HA plasmids. Derivatives of the human colon carcinoma cell line DLD1 expressing either p21HA, p21 CDK7 HA, or p21 PCNA7 HA under the control of a tetracycline-regulated promoter, were generated as previously described . These stable cell lines were maintained in Dulbecco's modi®ed Eagle's medium (DMEM; Seromed), supplemented with 10% foetal calf serum (FCS; Eurobio) and tetracycline (2 mg/ml; Sigma). Expression of wild-type or mutated p21 was induced by culture in the same medium without tetracycline. Transient transfection experiments were carried out using the calcium phosphate coprecipitation method, with 20 mg expression vector per 100 mm dish. Forty-eight hours after the transfection, cells were treated or not with protease inhibitors, and subjected to pulse-chase or Western blotting analysis.
Proteolysis inhibitor treatment

